To avoid uterine cervical cancer, 1,700 adolescents and young women from San Carlos were vaccinated against human papillomavirus (HPV).
The work is done by the Costa Rican Agency for Biomedical Research (ACIB) as part of the study, which shows that single dose is as effective as applying two.
The vaccination process started on 7 December and will continue until February 2020 until the participants are hired and then continued for another four years.
Data from the National Tumor Register shows that in this canton of Aladjueva 25 women died of cervical cancer between 2011 and 2015. This is a percentage of 5.6 cases per 100,000 women per year.
"Cervical cancer continues to claim the lives of hundreds of thousands of women every year, especially in the poorest countries, despite the fact that we have tools to prevent it, such as early detection and HPV vaccination," said Paula Gonzalez, Director of ACIB.
"The vaccine does not apply in all countries that need it because of the high cost and two doses are needed, so we conducted the study to show that one dose is sufficient and can provide more protection for more women in the world." he added.
Vaccines are used in a comparison of one and two-dose HPV (Escuddo) study, which includes 24,000 young and adolescent women between 12 and 20 years of age.
This dose will be obtained from women from 50 cantons across the country except for Limón province because of the complexity of the transfer of samples.
So far only 6,500 of 24,000 women have been summoned to participate in the trial.
The World Health Organization (WHO) recommends that adolescents under the age of 15 apply two doses and the vaccine be included in national immunization programs in all countries.
The cervical cancer vaccine is part of the national vaccination program in 80 countries. In Costa Rica, he is approved by the Ministry of Health and will be included in the Costa Rican Social Security Fund (CCSS) programs for 10-year-old girls starting in 2019.